88 Energy “days away” from HRZ target

|

Published 27-NOV-2015 14:50 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

88 Energy (ASX:88E) is back on track at Icewine-1 and is “only days away” from hitting the target HRZ shale.

The oil and gas company told its investors today that after delays, drilling was back on track and would be back drilling after a statutory test of a blow out preventer.

It said the various delays on the well had not materially affected its budget on the well, with Icewine-1 still expected to come in under budget.

The well is currently sitting at 8773 feet (2674m), and has a planned total depth of 11,600ft.

The potential strategic upside of Icewine-1 recently tripled for 88E after it effectively tripled its acreage position at the project by picking up more land at government auction together with joint venture partner Burgundy Xploration.

This means the joint venture now has its foot (subject to final payments) on a contiguous acreage position of 272,242 acres in total.

The extra acreage 88E has picked up

The extra acreage 88E has picked up

88E has previously said that the increased acreage position effectively means the company has a recoverable estimate of 2 billion barrels of oil from the HRZ, previously 813.2 million barrels of the high side.

Drilling into the HRZ from other operators in the area has shown porosity at the HRZ to be 18.4%, which is estimated to be 50% better than that seen in the prolific Eagle Ford Shale in Texas.

Icewine-1 and possible follow-up Icewine-2 are being seen as vital to 88E’s chances of jagging a major oil company into a farm-in transaction.

“Whilst we do not have definitive data that the HRZ play will be successful, the option value associated with the success case versus the relatively small down payment required is an opportunity than cannot be passed up,” 88E managing director Dave Wall previously said.

“Any success at Icewine-1 will result in substantial industry interest, which we hope will lead to a highly accretive farmout in 2016.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X